Table 4 Treatment and consequences of CIT requiring inpatient or outpatient care
From: Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice
All Agents | |
|---|---|
(n = 27,913) | |
Number of CIT-Related Hospital Admissions, mean per patient-episode (95% CI) | 0.03 (0.03–0.03) |
Characteristics of Admissions (i.e., per admission) | |
LOS, days, mean (95% CI) | 4.6 (4.4–5.0) |
Mortalitya, % (95% CI) | 4.7 (2.8–6.6) |
Diagnoses, % (95% CI) | |
CIT Only | 7.7 (5.7–9.6) |
Bleeding Only | 85.2 (82.5–87.6) |
CIT and Bleeding | 7.1 (5.4–9.1) |
Cost ($), mean per admission (95% CI) | 36,448 (32,332 - 41,331) |
Number of Hospital Days, mean per patient-episode (95% CI) | 0.13 (0.12–0.14) |
Cost of Admissions ($), mean per patient-episode (95% CI) | 1024 (881–1167) |
Number of CIT-Related Ambulatory Encounters, mean per patient-episode (95% CI) | 3.7 (3.7–3.8) |
Characteristics of Outpatient Encounters (i.e., per encounter) | |
Setting of Care, % (95% CI) | |
Physician Office | 44.6 (44.3–44.9) |
Emergency Department | 2.2 (2.1–2.3) |
Hospital Outpatient | 40.7 (40.4–41.0) |
Labs | 4.5 (4.4–4.6) |
Other | 8.0 (7.8–8.1) |
Diagnoses, % (95% CI) | |
CIT Only | 16.2 (16.0–16.4) |
Bleeding Only | 15.8 (15.6–16.0) |
CIT and Bleeding | 0.4 (0.4–0.5) |
None of the Above | 67.5 (67.2–67.8) |
Procedures, % (95% CI) | |
Blood Product Transfusion | |
Platelet | 2.0 (1.9–2.1) |
Red Blood | 3.1 (3.0–3.2) |
Stem Cell | 0.2 (0.2–0.2) |
Whole Blood | 0.0 (0.0–0.0) |
Other | 0.4 (0.3–0.4) |
Coagulation Factor Transfusion | 0.0 (0.0–0.0) |
Control of Bleeding | 0.7 (0.6–0.7) |
Labs | 64.1 (63.8–64.4) |
Pharmacotherapy, % (95% CI) | |
Glucocorticosteroid | 28.3 (28.0–28.6) |
Immunoglobulin | 0.0 (0.0–0.0) |
Thrombopoietin Receptor Agonists | |
Eltrombopag | --- |
Romiplostim | 0.0 (0.0–0.0) |
Cost ($), mean per encounter (95% CI) | |
Physician Office | 123 (121–125) |
Emergency Department | 839 (779–918) |
Hospital Outpatient | 504 (486–524) |
Labs | 11 (11–11) |
Other | 359 (337–383) |
Cost of Ambulatory Encounters ($), mean per patient-episode (95% CI) | 1153 (1119 - 1187) |
Characteristics of Outpatient Pharmacotherapy | |
Number of Filled Prescriptions, mean per patient-episode (95% CI) | 0.2 (0.2–0.2) |
Glucocorticosteroid, % (95% CI) | 99.9 (99.8–100.0) |
Immunoglobulin, % (95% CI) | 0.1 (0.0–0.1) |
Thrombopoietin Receptor Agonists, % (95% CI) | |
Eltrombopag | 0.0 (0.0–0.1) |
Romiplostim | 0 |
Cost ($), mean per prescription (95% CI) | |
Glucocorticosteroid | 10 (10–11) |
Immunoglobulin | 7302 (6735 - 7869) |
Thrombopoietin Receptor Agonists | |
Eltrombopag | 5640 (5038 - 6242) |
Romiplostim | 0 |
Cost of Prescriptions ($), mean per patient-episode (95% CI) | 3 (2–4) |
Total Cost per Cycle ($), mean per patient-episode | 2179 (2029 - 2329) |